<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36813162</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</Title><ISOAbbreviation>J Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Characteristics of hospitalized COVID-19 patients with other respiratory pathogens identified by rapid diagnostic test.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>545</EndPage><MedlinePgn>539-545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiac.2023.02.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1341-321X(23)00042-9</ELocationID><Abstract><AbstractText>Rapid diagnostic tests (RDTs) significantly impact disease treatment strategy. In Japan, information on the use of RDTs for patients with COVID-19 is limited. Here, we aimed to investigate the RDT implementation rate, pathogen detection rate, and clinical characteristics of patients positive for other pathogens by using COVIREGI-JP, a national registry of hospitalized patients with COVID-19. A total of 42,309 COVID-19 patients were included. For immunochromatographic testing, influenza was the most common (n = 2881 [6.8%]), followed by Mycoplasma pneumoniae (n = 2129 [5%]) and group A streptococcus (GAS) (n = 372 [0.9%]). Urine antigen testing was performed for 5524 (13.1%) patients for S. pneumoniae and for 5326 patients (12.6%) for L. pneumophila. The completion rate of M. pneumonia loop-mediated isothermal amplification (LAMP) testing was low (n = 97 [0.2%]). FilmArray RP was performed in 372 (0.9%) patients; 1.2% (36/2881) of patients were positive for influenza, 0.9% (2/223) for the respiratory syncytial virus (RSV), 9.6% (205/2129) for M. pneumoniae, and 7.3% (27/372) for GAS. The positivity rate for urine antigen testing was 3.3% (183/5524) for S. pneumoniae and 0.2% (13/5326) for L. pneumophila. The positivity rate for LAMP test was 5.2% (5/97) for M. pneumoniae. Five of 372 patients (1.3%) had positive FilmArray RP, with human enterovirus being the most frequently detected (1.3%, 5/372). The characteristics of patients with and without RDTs submission and positive and negative results differed for each pathogen. RDTs remain an important diagnostic tool in patients with COVID-19 in whom coinfection with other pathogens needs to be tested based on clinical evaluation.</AbstractText><CopyrightInformation>Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: michisuzuki@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayakawa</LastName><ForeName>Kayoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asai</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitajima</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuzuki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriya</LastName><ForeName>Ataru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moriya</LastName><ForeName>Kyoji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan; Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchiyama-Nakamura</LastName><ForeName>Fukumi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Infect Chemother</MedlineTA><NlmUniqueID>9608375</NlmUniqueID><ISSNLinking>1341-321X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000092025" MajorTopicYN="N">Rapid Diagnostic Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009177" MajorTopicYN="N">Mycoplasma pneumoniae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Co-detection</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36813162</ArticleId><ArticleId IdType="pmc">PMC9939390</ArticleId><ArticleId IdType="doi">10.1016/j.jiac.2023.02.006</ArticleId><ArticleId IdType="pii">S1341-321X(23)00042-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Musuuza J.S., Watson L., Parmasad V., Putman-Buehler N., Christensen L., Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021;16 doi: 10.1371/journal.pone.0251170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251170</ArticleId><ArticleId IdType="pmc">PMC8101968</ArticleId><ArticleId IdType="pubmed">33956882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y., Maejima M., Shibusawa M., Amemiya K., Nagakubo Y., Hosaka K., et al. Analysis of Covid-19 and non-Covid-19 viruses, including influenza viruses, to determine the influence of intensive preventive measures in Japan. J Clin Virol. 2020;129 doi: 10.1016/j.jcv.2020.104543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104543</ArticleId><ArticleId IdType="pmc">PMC7340051</ArticleId><ArticleId IdType="pubmed">32663787</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga N., Hayakawa K., Terada M., et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY Japan. Clin. Infect. Dis. 1 December 2021;73(11):e3677–e3689. [published online ahead of print, September 28 2020]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543311</ArticleId><ArticleId IdType="pubmed">32986793</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., et al. Remdesivir for the treatment of covid-19 – final report. N Engl J Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>NIID National Institute of Infectious Disease  Influenza Pathogen Surveillance Trends in influenza virus positive and negative cases reported to the NESID: national Epidemiological Surveillance of Infectious Disease System by season and the usefulness of this information. https://www.niid.go.jp/niid/ja/flu-m/flu-iasrd/11091-506d02.html</Citation></Reference><Reference><Citation>Sawakami T., Karako K., Song P. Behavioral changes adopted to constrain COVID-19 in Japan: what are the implications for seasonal influenza prevention and control? Glob Health Med. 2021;3:125–128. doi: 10.35772/ghm.2021.01066.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2021.01066</ArticleId><ArticleId IdType="pmc">PMC8239374</ArticleId><ArticleId IdType="pubmed">34250286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.H., Min I.K., Ahn J.G. Immunochromatography for the diagnosis of Mycoplasma pneumoniae infection: a systematic review and meta-analysis. PLoS One. 2020 Mar 17;15(3) doi: 10.1371/journal.pone.0230338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0230338</ArticleId><ArticleId IdType="pmc">PMC7077834</ArticleId><ArticleId IdType="pubmed">32182283</ArticleId></ArticleIdList></Reference><Reference><Citation>NIID national institute of infectious disease. https://www.niid.go.jp/niid/ja/data.html IDWR Surveillance Data Table 2022 week 27 available at:,</Citation></Reference><Reference><Citation>Matsunaga N., Hayakawa K., Asai Y., Tsuzuki S., Terada M., Suzuki S., et al. Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study. Lancet Reg Health West Pac. 2022;22 doi: 10.1016/j.lanwpc.2022.100421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2022.100421</ArticleId><ArticleId IdType="pmc">PMC8923875</ArticleId><ArticleId IdType="pubmed">35300186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>